Welcome to our dedicated page for Lucid Diagnostics SEC filings (Ticker: LUCD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Lucid Diagnostics Inc. (NASDAQ: LUCD), a commercial-stage, cancer prevention medical diagnostics company focused on esophageal precancer detection in patients with gastroesophageal reflux disease (GERD). Through these filings, investors can review the company’s official disclosures on financial performance, capital structure, and material corporate events.
Current reports on Form 8-K document significant events such as quarterly financial results, public offerings of common stock, and board appointments. For example, Lucid has filed 8-Ks to furnish press releases announcing financial results for quarters ended June 30 and September 30, 2025, to report the entry into and closing of an underwritten public offering of common stock under a shelf registration statement on Form S-3, and to disclose the appointment of a new director designated by holders of its convertible secured promissory notes.
Periodic reports such as Forms 10-Q and 10-K, referenced in Lucid’s press releases and 8-K filings, contain detailed financial statements, management’s discussion and analysis, and additional information about its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device business. These documents explain how the company reports EsoGuard-related revenues, operating expenses, and non-GAAP measures such as EBITDA and non-GAAP adjusted loss.
Investors can also find information on securities offerings and agreements in Lucid’s filings. An 8-K dated September 10, 2025 describes an underwriting agreement for an underwritten public offering of common stock, including the number of shares, public offering price, underwriting discount, and use of proceeds for working capital and general corporate purposes. A subsequent 8-K dated September 11, 2025 reports the closing of that offering and the expected net proceeds.
Stock Titan’s interface surfaces these SEC filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each filing. Real-time updates from the EDGAR system ensure that new 8-Ks, 10-Qs, 10-Ks, and other forms are added as they are filed, while Form 4 and related insider transaction reports, when available, can be reviewed to analyze trading activity by Lucid’s officers, directors, or significant shareholders.
Lucid Diagnostics Inc. is asking stockholders to elect three Class B directors, approve a major increase in authorized common shares, and ratify CBIZ CPAs P.C. as auditor at its June 24, 2026 virtual annual meeting.
The Authorized Capital Proposal would raise authorized common stock from 300,000,000 to 400,000,000 shares. As of April 27, 2026, 195,253,423 common shares were outstanding and large additional blocks were reserved for options, preferred stock and convertible notes, so more authorized shares would support financings, equity awards and conversions but could dilute existing holders and be used in anti-takeover contexts. PAVmed, the parent company, plans to vote in favor of all proposals.
Lucid Diagnostics Inc. Chief Medical Officer Victoria Lee Tou-ho filed an amended Form 3 updating her equity holdings. She reports 650,000 shares of Common Stock, representing restricted stock granted under the company’s 2018 Equity Plan with specific future vesting dates.
The restricted stock comprises 200,000 shares granted on November 6, 2023 vesting November 6, 2026; 150,000 shares granted February 20, 2025 vesting May 20, 2028; and 300,000 shares granted February 20, 2026 vesting May 20, 2029, all subject to forfeiture if service requirements are not met. She also holds an employee stock option for 100,000 shares of Common Stock at an exercise price of $1.25 per share, expiring on February 22, 2034, with one-third already vested and the remainder vesting in equal quarterly installments through December 31, 2026.
Lucid Diagnostics Inc. closed an underwritten public offering of 18,000,000 shares of common stock at $1.00 per share, raising gross proceeds of approximately $18 million. Net proceeds are expected to be about $16.8 million after underwriting discounts and expenses.
The company plans to use the net proceeds for working capital and general corporate purposes, helping fund its commercial-stage cancer prevention diagnostics business. The offering was made under an effective shelf registration statement on Form S-3, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners.
Lucid Diagnostics is offering 18,000,000 shares of common stock at $1.00 per share. The prospectus supplement states an underwriting discount of $0.06 per share and estimated net proceeds to the company of approximately $16.8 million after underwriting discounts and estimated offering expenses.
Following the offering the company reports 195,253,423 shares of common stock outstanding. The shares are listed on the Nasdaq Capital Market under the symbol LUCD. Officers and directors agreed to 45-day lock-ups after closing. The supplement discloses expected delivery on or about April 24, 2026.
Lucid Diagnostics Inc. is raising $18,000,000 through an underwritten public offering of 18,000,000 common shares at a public offering price of $1.00 per share. Underwriters will purchase the shares at $0.94 per share, reflecting a $0.06 per-share underwriting discount, and will be reimbursed for certain expenses up to $75,000.
The company expects the sale to close on or about April 24, 2026, subject to customary conditions, with Canaccord Genuity and BTIG acting as joint bookrunners. The offering is made from Lucid’s effective Form S-3 shelf registration, and a related press release notes that the company intends to use net proceeds for working capital and general corporate purposes.
Lucid Diagnostics Inc. is asking shareholders at its virtual Annual Meeting to elect three Class B directors, ratify CBIZ CPAs P.C. as independent auditors, and approve an amendment to increase authorized common stock by 100,000,000 shares (from 300,000,000 to 400,000,000).
The Board set the record date as April 27, 2026 and scheduled the meeting for June 24, 2026 at 11:00 a.m. Eastern as a webcast. The Board and parent PAVmed support the proposals; the amendment would permit the Board to issue additional shares without further stockholder approval.
Lucid Diagnostics Inc. reported initial share ownership for Chief Medical Officer Lee Victoria Tou-ho. The filing shows direct ownership of 650,000 shares of common stock, including restricted stock granted under the company’s 2018 Equity Plan that vests over several future dates and can be forfeited if service requirements are not met.
The restricted stock grants consist of 200,000 shares awarded November 6, 2023 vesting on November 6, 2026, 150,000 shares awarded February 20, 2025 vesting on May 20, 2028, and 300,000 shares awarded February 20, 2026 vesting on May 20, 2029, all subject to continued service.
Lucid Diagnostics Inc. proposes to offer up to $25,000,000 of common stock through an at-the-market offering under a sales agreement with Maxim Group LLC.
The shares may be sold from time to time at prevailing market prices; Maxim will act as agent or principal and receive a 3.0% commission. Net proceeds, if any, are intended for working capital and general corporate purposes.